Navigation Links
Quantitation of the Protein MIA as a Marker for,,,Chondrocytes in Research Samples

MIA (Melanoma Inhibitory Activity) was cloned as a secreted protein from human melanoma cell lines [1]. MIA is expressed in and secreted from malignant melanomas and chondrocytes [2, 3]. As MIA expression in chondrocytes is dependent on the differentiation status of the cells it was also designated CD-RAP (cartilage-derived retinoic acid sensitive protein). Retinoic acid is known as a regulator of chondrocytic cell differentiation in vitro.

Recent results indicate an important role in tumor progression and metastasis as MIA mediates detachment of melanoma cells from extracellular matrix molecules such as fibronectin [4]. MIA expression levels closely parallel the capability of melanoma cells to form metastases in syngeneic animals. Recently, MIA-deficient mice were shown to have structural abnormalities in cartilage [5].

Materials and Methods

Cell culture

Human primary chondrocytes derived from articular cartilage were cultivated in DMEM supplemented with penicillin (100 U/ml), streptomycin (10 g/ml) (both Sigma), and 10 % fetal calf serum (Gibco) under a humidified atmosphere of 5% CO2 at 37 C, then split 1:2 at 80 % confluency. As chondrocytes spontaneously dedifferentiate in cell culture, redifferentiation of the cells was induced by treatment with transforming growth factor-b (TGF-b) for 4 days. Differentiation was controlled by determining collagen type II with RT-PCR. Human mesenchymal stem cells were obtained from BioWhittaker Europe (Poietics) and cultured as described by the manufacturer.

MIA-ELISA

MIA was measured by a commercially available ELISA (Roche Applied Science), the manufacturers instructions were precisely followed and the internal standard reagents provided were used.

Results and Application

MIA as a potential marker for chondrocyte differentiation and chondrocytic disorders

High levels of MIA expression were observed in differentiated chondrocytes. As a result, MIA was also investigated as a potential marker for cartilage tissue engineering and cartilage damage.

In cell culture of chondrocytes and tissue engineering of cartilage cell differentiation must be carefully monitored. The detection of collagen type II as a marker for chondrocytic differentiation is commonly used. However, using this marker does create problems as ELISAs are not feasible, and for RNA analysis, the cells are lost during extraction procedures. Therefore we established MIA as a chondrocytic marker.
MIA is a secreted molecule, making it easy to measure its levels in the cell culture supernatant. Detection by the MIA-ELISA is highly specific, sensitive, and quantitative. In cell-culture systems using human chondrocytes (Figure 1) and human mesenchymal stem cells (Figure 2), we were able to monitor the process of cell differentiation.

MIA serum concentrations in individuals with different rheumatic diseases were measured, correlated with inflammatory parameters and/or with the degree of joint destruction, and compared with healthy individuals and subjects suffering from melanoma [6]. Increased MIA serum concentrations were only found in individuals with rheumatic diseases associated with joint destruction, such as rheumatoid arthritis, osteoarthritis, HLA B27-associated oligoarthritis, and psoriatic arthritis. Within these rheum atic diseases, the most significant increase in MIA serum concentrations was measured in subjects with rheumatoid arthritis, associated with rheumatoid factor positivity and joint destruction. Therefore, MIA may be useful to discriminate rheumatoid arthritis from nondestructive rheumatic diseases. Further studies are necessary to confirm these preliminary findings.

Our studies indicate that MIA may be a useful marker for cartilage diseases and the monitoring of chondrocytic differentiation in cell culture. We conclude that MIA has the potential to replace other markers due to its improved applicability.


'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Quantitation of Cabergoline at Extremely Low Plasma Concentrations with a Triple Quadrupole Mass Spectrometer
2. Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine in Bovine Plasma using the TSQ Quantum Mass Spectrometer
3. Comparison of Different Methods of mRNA Quantitation
4. Quantitation of DNA for Automated Sequencing Using the VersaFluor Fluorometer
5. Quantitation of RNA for Hybridization Blots Using the VersaFluor Fluorometer
6. Quantitation of Lymphangiogenesis Using the iCycler iQ Real-Time PCR Detection System and Scorpions Detection System, Rev A
7. Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A
8. Benchmark Plus Microplate Reader: Quantitation of Protein Concentration Using Two Different Colorimetric Assay Kits, Rev A
9. A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders
10. A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)
11. Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused on ... of Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine product ... is expected to deliver therapeutic levels of olanzapine for a period of 3 months., ...
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing ... financial results for the third quarter and first nine ... Third Quarter of Fiscal 2017 Highlights ... 2017 increased by 18.6% to RMB200.9 million ($28.9 million). ...
Breaking Biology Technology:
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/7/2017)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the latest release of ... and award winning eClinical solution, is now available for ... a proven Software-as-a-Service (SaaS) clinical research technology platform that ... delivers an entire suite of eClinical tools to support ...
(Date:2/3/2017)... Biomedical Research Institute announced that its Board of Trustees has ... Institute,s new President and CEO. Dr. Schlesinger will take the ... currently the Chair of the Department of Microbial Infection and ... at Ohio State University. "We are delighted to ... Texas Biomed," said Dr. James O. Rubin , Board ...
Breaking Biology News(10 mins):